TY - JOUR
T1 - SARS-CoV-2 viral load is associated with increased disease severity and mortality
AU - The Massachusetts Consortium for Pathogen Readiness
AU - Fajnzylber, Jesse
AU - Regan, James
AU - Coxen, Kendyll
AU - Corry, Heather
AU - Wong, Colline
AU - Rosenthal, Alexandra
AU - Worrall, Daniel
AU - Giguel, Francoise
AU - Piechocka-Trocha, Alicja
AU - Atyeo, Caroline
AU - Fischinger, Stephanie
AU - Chan, Andrew
AU - Flaherty, Keith T.
AU - Hall, Kathryn
AU - Dougan, Michael
AU - Ryan, Edward T.
AU - Gillespie, Elizabeth
AU - Chishti, Rida
AU - Li, Yijia
AU - Jilg, Nikolaus
AU - Hanidziar, Dusan
AU - Baron, Rebecca M.
AU - Baden, Lindsey
AU - Tsibris, Athe M.
AU - Armstrong, Katrina A.
AU - Kuritzkes, Daniel R.
AU - Alter, Galit
AU - Walker, Bruce D.
AU - Yu, Xu
AU - Li, Jonathan Z.
AU - Abayneh, Betelihem A.(Betty)
AU - Allen, Patrick
AU - Antille, Diane
AU - Balazs, Alejandro
AU - Bals, Julia
AU - Barbash, Max
AU - Bartsch, Yannic
AU - Boucau, Julie
AU - Boyce, Siobhan
AU - Braley, Joan
AU - Branch, Karen
AU - Broderick, Katherine
AU - Carney, Julia
AU - Chevalier, Josh
AU - Choudhary, Manish C.
AU - Chowdhury, Navin
AU - Cordwell, Trevor
AU - Daley, George
AU - Davidson, Susan
AU - Desjardins, Michael
N1 - Publisher Copyright:
© 2020, The Author(s).
PY - 2020/12/1
Y1 - 2020/12/1
N2 - The relationship between SARS-CoV-2 viral load and risk of disease progression remains largely undefined in coronavirus disease 2019 (COVID-19). Here, we quantify SARS-CoV-2 viral load from participants with a diverse range of COVID-19 disease severity, including those requiring hospitalization, outpatients with mild disease, and individuals with resolved infection. We detected SARS-CoV-2 plasma RNA in 27% of hospitalized participants, and 13% of outpatients diagnosed with COVID-19. Amongst the participants hospitalized with COVID-19, we report that a higher prevalence of detectable SARS-CoV-2 plasma viral load is associated with worse respiratory disease severity, lower absolute lymphocyte counts, and increased markers of inflammation, including C-reactive protein and IL-6. SARS-CoV-2 viral loads, especially plasma viremia, are associated with increased risk of mortality. Our data show that SARS-CoV-2 viral loads may aid in the risk stratification of patients with COVID-19, and therefore its role in disease pathogenesis should be further explored.
AB - The relationship between SARS-CoV-2 viral load and risk of disease progression remains largely undefined in coronavirus disease 2019 (COVID-19). Here, we quantify SARS-CoV-2 viral load from participants with a diverse range of COVID-19 disease severity, including those requiring hospitalization, outpatients with mild disease, and individuals with resolved infection. We detected SARS-CoV-2 plasma RNA in 27% of hospitalized participants, and 13% of outpatients diagnosed with COVID-19. Amongst the participants hospitalized with COVID-19, we report that a higher prevalence of detectable SARS-CoV-2 plasma viral load is associated with worse respiratory disease severity, lower absolute lymphocyte counts, and increased markers of inflammation, including C-reactive protein and IL-6. SARS-CoV-2 viral loads, especially plasma viremia, are associated with increased risk of mortality. Our data show that SARS-CoV-2 viral loads may aid in the risk stratification of patients with COVID-19, and therefore its role in disease pathogenesis should be further explored.
UR - https://www.scopus.com/pages/publications/85094827682
U2 - 10.1038/s41467-020-19057-5
DO - 10.1038/s41467-020-19057-5
M3 - Article
C2 - 33127906
AN - SCOPUS:85094827682
SN - 2041-1723
VL - 11
JO - Nature Communications
JF - Nature Communications
IS - 1
M1 - 5493
ER -